Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009

D. E. Furst; E. C. Keystone; R. Fleischmann; P. Mease; F. C. Breedveld; J. S. Smolen; J. R. Kalden; J. Braun; B. Bresnihan; G. R. Burmester; F. De Benedetti; T. Doerner; P. Emery; A. Gibofsky; A. Kavanaugh; Bruce Kirkham; M. H. Schiff; J. Sieper; N. Singer; P. L. C. M. Van Riel; M. E. Weinblatt; M. H. Weisman; K. Winthrop

doi:10.1136/ard.2009.123885

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009

D. E. Furst^*, E. C. Keystone, R. Fleischmann, P. Mease, F. C. Breedveld, J. S. Smolen, J. R. Kalden, J. Braun, B. Bresnihan, G. R. Burmester, F. De Benedetti, T. Doerner, P. Emery, A. Gibofsky, A. Kavanaugh, Bruce Kirkham, M. H. Schiff, J. Sieper, N. Singer, P. L. C. M. Van RielM. E. Weinblatt, M. H. Weisman, K. Winthrop

^*Corresponding author for this work

Research output: Contribution to journal › Literature review › peer-review

131 Citations (Scopus)

Abstract

As in previous years, the consensus group to consider the use of biological agents in the treatment of rheumatic diseases met during the 11th Annual Workshop on Advances in Targeted Therapies. The group consisted of rheumatologists from a number of universities among the continents of Europe, North America, South America, Australia and Asia.

Pharmaceutical industry support was obtained from a number of companies for the annual workshop itself but these companies had no part in the decisions about the specific programme or about the academic participants at this conference. Representatives of the supporting sponsors participated in the initial working groups to supply factual information. The sponsors did not participate in the drafting of the consensus statement.

This consensus was prepared from the perspective of the treating physician.

Original language	English
Pages (from-to)	i2-i29
Number of pages	28
Journal	Annals of the Rheumatic Diseases
Volume	69
DOIs	https://doi.org/10.1136/ard.2009.123885
Publication status	Published - Jan 2010

Keywords

TUMOR-NECROSIS-FACTOR
SYSTEMIC-LUPUS-ERYTHEMATOSUS
B-CELL DEPLETION
PLACEBO-CONTROLLED TRIAL
INTERLEUKIN-1 RECEPTOR ANTAGONIST
ALPHA MONOCLONAL-ANTIBODY
MODIFYING ANTIRHEUMATIC DRUGS
JUVENILE IDIOPATHIC ARTHRITIS
RANDOMIZED CONTROLLED-TRIALS
ONSET STILLS-DISEASE

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/ard.2009.123885

Cite this

Furst, D. E., Keystone, E. C., Fleischmann, R., Mease, P., Breedveld, F. C., Smolen, J. S., Kalden, J. R., Braun, J., Bresnihan, B., Burmester, G. R., De Benedetti, F., Doerner, T., Emery, P., Gibofsky, A., Kavanaugh, A., Kirkham, B., Schiff, M. H., Sieper, J., Singer, N., ... Winthrop, K. (2010). Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Annals of the Rheumatic Diseases, 69, i2-i29. https://doi.org/10.1136/ard.2009.123885

@article{5bfebbf4ec974a809342decb5d0f995d,

title = "Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009",

abstract = "As in previous years, the consensus group to consider the use of biological agents in the treatment of rheumatic diseases met during the 11th Annual Workshop on Advances in Targeted Therapies. The group consisted of rheumatologists from a number of universities among the continents of Europe, North America, South America, Australia and Asia.Pharmaceutical industry support was obtained from a number of companies for the annual workshop itself but these companies had no part in the decisions about the specific programme or about the academic participants at this conference. Representatives of the supporting sponsors participated in the initial working groups to supply factual information. The sponsors did not participate in the drafting of the consensus statement.This consensus was prepared from the perspective of the treating physician.",

keywords = "TUMOR-NECROSIS-FACTOR, SYSTEMIC-LUPUS-ERYTHEMATOSUS, B-CELL DEPLETION, PLACEBO-CONTROLLED TRIAL, INTERLEUKIN-1 RECEPTOR ANTAGONIST, ALPHA MONOCLONAL-ANTIBODY, MODIFYING ANTIRHEUMATIC DRUGS, JUVENILE IDIOPATHIC ARTHRITIS, RANDOMIZED CONTROLLED-TRIALS, ONSET STILLS-DISEASE",

author = "Furst, {D. E.} and Keystone, {E. C.} and R. Fleischmann and P. Mease and Breedveld, {F. C.} and Smolen, {J. S.} and Kalden, {J. R.} and J. Braun and B. Bresnihan and Burmester, {G. R.} and {De Benedetti}, F. and T. Doerner and P. Emery and A. Gibofsky and A. Kavanaugh and Bruce Kirkham and Schiff, {M. H.} and J. Sieper and N. Singer and {Van Riel}, {P. L. C. M.} and Weinblatt, {M. E.} and Weisman, {M. H.} and K. Winthrop",

year = "2010",

month = jan,

doi = "10.1136/ard.2009.123885",

language = "English",

volume = "69",

pages = "i2--i29",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "BMJ Publishing Group",

}

Furst, DE, Keystone, EC, Fleischmann, R, Mease, P, Breedveld, FC, Smolen, JS, Kalden, JR, Braun, J, Bresnihan, B, Burmester, GR, De Benedetti, F, Doerner, T, Emery, P, Gibofsky, A, Kavanaugh, A, Kirkham, B, Schiff, MH, Sieper, J, Singer, N, Van Riel, PLCM, Weinblatt, ME, Weisman, MH & Winthrop, K 2010, 'Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009', Annals of the Rheumatic Diseases, vol. 69, pp. i2-i29. https://doi.org/10.1136/ard.2009.123885

TY - JOUR

T1 - Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009

AU - Furst, D. E.

AU - Keystone, E. C.

AU - Fleischmann, R.

AU - Mease, P.

AU - Breedveld, F. C.

AU - Smolen, J. S.

AU - Kalden, J. R.

AU - Braun, J.

AU - Bresnihan, B.

AU - Burmester, G. R.

AU - De Benedetti, F.

AU - Doerner, T.

AU - Emery, P.

AU - Gibofsky, A.

AU - Kavanaugh, A.

AU - Kirkham, Bruce

AU - Schiff, M. H.

AU - Sieper, J.

AU - Singer, N.

AU - Van Riel, P. L. C. M.

AU - Weinblatt, M. E.

AU - Weisman, M. H.

AU - Winthrop, K.

PY - 2010/1

Y1 - 2010/1

N2 - As in previous years, the consensus group to consider the use of biological agents in the treatment of rheumatic diseases met during the 11th Annual Workshop on Advances in Targeted Therapies. The group consisted of rheumatologists from a number of universities among the continents of Europe, North America, South America, Australia and Asia.Pharmaceutical industry support was obtained from a number of companies for the annual workshop itself but these companies had no part in the decisions about the specific programme or about the academic participants at this conference. Representatives of the supporting sponsors participated in the initial working groups to supply factual information. The sponsors did not participate in the drafting of the consensus statement.This consensus was prepared from the perspective of the treating physician.

AB - As in previous years, the consensus group to consider the use of biological agents in the treatment of rheumatic diseases met during the 11th Annual Workshop on Advances in Targeted Therapies. The group consisted of rheumatologists from a number of universities among the continents of Europe, North America, South America, Australia and Asia.Pharmaceutical industry support was obtained from a number of companies for the annual workshop itself but these companies had no part in the decisions about the specific programme or about the academic participants at this conference. Representatives of the supporting sponsors participated in the initial working groups to supply factual information. The sponsors did not participate in the drafting of the consensus statement.This consensus was prepared from the perspective of the treating physician.

KW - TUMOR-NECROSIS-FACTOR

KW - SYSTEMIC-LUPUS-ERYTHEMATOSUS

KW - B-CELL DEPLETION

KW - PLACEBO-CONTROLLED TRIAL

KW - INTERLEUKIN-1 RECEPTOR ANTAGONIST

KW - ALPHA MONOCLONAL-ANTIBODY

KW - MODIFYING ANTIRHEUMATIC DRUGS

KW - JUVENILE IDIOPATHIC ARTHRITIS

KW - RANDOMIZED CONTROLLED-TRIALS

KW - ONSET STILLS-DISEASE

U2 - 10.1136/ard.2009.123885

DO - 10.1136/ard.2009.123885

M3 - Literature review

SN - 0003-4967

VL - 69

SP - i2-i29

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

ER -

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this